Claims

1. ~~A composition~~Use of an estetrol component in the manufacture of a medicament for ~~use in~~ alleviating menopause-associated symptoms selected from the group consisting of: psychological menopause-associated symptoms, joint pain and diabetes, wherein said ~~composition comprises an~~ estetrol component ~~and wherein said composition~~ is to be administered at a daily amount equivalent to from about 15 mg to about 25 mg ~~of estetrol~~.

2. The use according to claim 1, wherein the menopause-associated symptoms are psychological menopause-associated symptoms selected from the group consisting of: insomnia, sleep disturbance, anxiety, nervous tension, and combinations thereof.

3. The use according to claim 1, wherein the menopause-associated symptoms are psychological symptoms or diabetes, preferably wherein the menopause-associated symptoms are psychological symptoms or diabetes and wherein said estetrol component is to be administered at a daily amount equivalent to from about 15 mg to about 20 mg.

4. The use according to claim 1, wherein the menopause-associated symptoms are joint pain and wherein said estetrol component is to be administered at a daily amount equivalent to from about 20 mg to about 25 mg.

5. The use according to any one of claims 1 to 4, wherein the estetrol component is to be administered at a daily amount equivalent to about 20 mg.

6. The use according to any one of claims 1 to 5, wherein the estetrol component is to be administered daily for at least 4, preferably at least 12 weeks.

7. The use according to any one of claims 1 to 6, further comprising a progestogenic component.

8. The use of claim 7, wherein said progestogenic component is selected from drospirenone, progesterone and dydrogesterone.

9. The use of claim 8, wherein progesterone is to be administered at a daily dose of from 50 mg to 200 mg.

10. The use of any one of claims 1 to 9, further comprising bazedoxifene.

11. The use according to any one of claims 1 to 10, wherein the estetrol component is estetrol, preferably estetrol monohydrate.

12. The use according to any one of claims 1 to 11, wherein the medicament is formulated as an oral dosage unit.

13. The use according to claim 12, wherein the oral dosage unit is formulated to correspond to a daily dosage unit.

14. The use according to any one of claims 10 to 13, wherein said medicament is present in a packaging unit comprising at least 14, preferably at least 21, even more preferably at least 28, containers for holding separately packaged and individually removable daily solid oral dosage units.

15. The use according to claim 14, wherein said packaging unit additionally comprises at least 10, preferably 12, more preferably 14, additional containers for holding separately packaged and individually removable daily, preferably solid, oral dosage units, wherein each additional container comprises at least one daily, preferably solid, oral dosage unit comprising a progestogenic component.

16. The use according to claim 15, wherein each of the additional containers for holding the dosage units comprising the progestogenic component are individually visually arranged next to a container holding a solid dosage unit comprising estetrol when these two solid dosage units have to be administered on the same day.

17. The use according to claim 15 or 16, wherein said progestogenic component is selected from drospirenone, progesterone and dydrogesterone.

18. The use according to claim 17, wherein said progestogenic component is progesterone and wherein each said additional container comprises at least one daily oral dosage unit comprising from about 50 mg about 200 mg of progesterone.

19. The use according to claim 15, wherein the packaging unit additionally comprises the same number of additional containers for holding separately packaged and individually removable daily, preferably solid, oral dosage units, wherein each additional container comprises at least one daily, preferably solid, oral dosage unit comprising a progestogenic component, preferably wherein said progestogenic component is selected from drospirenone, progesterone and dydrogesterone, even more preferably wherein said progestogenic component is progesterone.

20. The use according to claim 14, wherein at least 10, preferably 12, more preferably 14, of said daily solid oral dosage units additionally comprises a progestogenic component.

21. The use according to claim 20, wherein each said daily solid oral dosage unit additionally comprises a progestogenic component.

~~2. The composition for use of Claim 1 wherein a second composition comprising a progestogenic component is additionally used.~~

~~3. The composition for use of Claim 2 wherein said progestogenic component is selected from drospirenone, progesterone and dydrogesterone.~~

~~4. The composition for use of Claim 2 wherein progesterone is administered at a daily dose of from 50 mg to 200 mg.~~

~~5. The composition for use of Claim 1 wherein a second composition comprising bazedoxifene is additionally used.~~

~~6. A composition for use according to any one of Claims 2-5 wherein said second composition comprising a progestogenic component or bazedoxifene is the same as the composition comprising the estetrol component.~~

~~7. A composition for use according to any one of Claims 1-6 wherein the estetrol component is estetrol, preferably estetrol monohydrate.~~

~~8. A composition for use according to any of the preceding claims wherein the composition is formulated as an oral dosage unit.~~

~~9. The composition for use according to Claim 8 wherein the oral dosage unit is formulated to correspond to a daily dosage unit.~~

~~10. A packaging unit comprising at least 21, preferably at least 28, containers for holding separately packaged and individually removable daily solid oral dosage forms, wherein each container comprises at least one daily solid oral dosage form comprising from about 15 mg to about 25 mg of estetrol.~~

~~11. The packaging unit according to Claim 10, wherein the packaging unit additionally comprises at least 10, preferably 12, more preferably 14, additional containers for holding separately packaged and individually removable daily, preferably solid, oral dosage forms, wherein each additional container comprises at least one daily, preferably solid, oral dosage form comprising a progestogenic component.~~

~~12. The packaging unit according to Claim 11, wherein said progestogenic component is selected from drospirenone, progesterone and dydrogesterone.~~

~~13. The packaging unit according to Claim 12, wherein said progestogenic component is progesterone and wherein each said additional containers comprises at least one daily oral dosage form comprising about 200 mg of progesterone.~~

~~14. The packaging unit according to Claim 10, wherein the packaging unit additionally comprises the same number of additional containers for holding separately packaged and individually removable daily, preferably solid, oral dosage forms, wherein each additional container comprises at least one daily, preferably solid, oral dosage form comprising a progestogenic component, preferably wherein said progestogenic component is selected from drospirenone, progesterone and dydrogesterone, even more preferably wherein said progestogenic component is progesterone and wherein said additional container comprises at least one daily oral dosage form comprising about 100 mg of progesterone.~~

~~15. The packaging unit according to Claim 10, wherein each said daily solid oral dosage form additionally comprises a progestogenic component.~~